11.17.08
CHINA: Vertellus Specialties Inc. will expand its vitamin B3 manufacturing capacity in Nantong, Jiangsu, China, as part of an aggressive plan to increase its presence in the region. The company will build a 3-cyanopyridine production unit at Nantong with capacity of 7,000 metric tons a year. It expects to break ground on this project early next year.
The expansion of vitamin B3 production will be divided into two projects—an initial 3-cyanopyridine plant followed by a niacinamide niacin production facility. The 3-cyanopyridine plant is expected to be completed by the end of 2009.
“Our production expansion in China is an important step in a global, long-term strategy to meet the increased market demands for vitamin B3,” said Rich Preziotti, chief executive officer of Vertellus Specialties. “In August 2007, we expanded our U.S. pyridine/picolines production units and, in March 2008, we did the same with our pyridine/picolines production capacity in China. Together, these projects provided a 35% increase in capacity for beta picoline, a key raw material input used to produce 3-cyanopyridine and vitamin B3.”
The company has also completed a 25% expansion of its U.S. and European capacity for 3-cyanopyridine. More info: www.vertellus.com
The expansion of vitamin B3 production will be divided into two projects—an initial 3-cyanopyridine plant followed by a niacinamide niacin production facility. The 3-cyanopyridine plant is expected to be completed by the end of 2009.
“Our production expansion in China is an important step in a global, long-term strategy to meet the increased market demands for vitamin B3,” said Rich Preziotti, chief executive officer of Vertellus Specialties. “In August 2007, we expanded our U.S. pyridine/picolines production units and, in March 2008, we did the same with our pyridine/picolines production capacity in China. Together, these projects provided a 35% increase in capacity for beta picoline, a key raw material input used to produce 3-cyanopyridine and vitamin B3.”
The company has also completed a 25% expansion of its U.S. and European capacity for 3-cyanopyridine. More info: www.vertellus.com